International Journal of Hypertension / 2012 / Article / Tab 3

Clinical Study

Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension

Table 3

Adverse events with incidence ≥2%.

T80/H25 ( )V160/H25 ( )Placebo ( )

Patients with any adverse event, n (%)94 (27.9)73 (22.3)37 (42.5)
Upper respiratory tract infection, n (%)6 (1.8) 5 (1.5)3 (3.4)
Sinusitis, n (%)2 (0.6)4 (1.2)2 (2.3)
Headache, n (%)8 (2.4)7 (2.1)4 (4.6)
Dizziness, n (%)7 (2.1) 7 (2.1)3 (3.4)
US spelling-diarrhea n (%)5 (1.5)2 (0.6)3 (3.4)
Dry mouth, n (%)1 (0.3)1 (0.3)2 (2.3)
Vomiting, n (%)2 (0.6)2 (2.3)
Muscle spasm, n (%)3 (0.9)5 (1.5)2 (2.3)
Hypertension, n (%)5 (5.7)
Fatigue, n (%)6 (1.8)2 (0.6)2 (2.3)

T80/H25: telmisartan 80 mg/hydrochlorothiazide 25 mg; V160/H25: valsartan 80 mg/hydrochlorothiazide 25 mg.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.